Adjust Font Increase Font Decrease Font
  • Email
  • Print
  • RSS Feed

Media Releases

PhRMA Statement on India Supreme Court Decision on Glivec
WASHINGTON, D.C. (April 1, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani issued the following statement today: “PhRMA is very disappointed with the Indian Supreme Court’s decision to deny a patent on Glivec. This decision marks yet another example of the deteriorating innovation environment in India.  Innovation is critical in meeting unmet needs of patients and is particularly relevant in the context of changing healthcare systems. In order to solve the real health challenges of India’s patients, it is critically important that India promote a policy environment that supports continued research and development of new medicines for the health of patients in India and worldwide. Protecting intellectual...
Read more

Latest Releases

PhRMA Statement on Medicare Part D Premiums
8/7/2012
“Since its inception, Medicare Part D has provided good access to medicines at an affordable cost. This exemplary track record of success continues with today’s announcement by the Department of Health and Human Services that beneficiaries’ average monthly Part D premiums for 2013 will remain steady for the third consecutive year at $30 – 50 percent less than original premium projections.
More
PhRMA Statement on Prescription Drug Costs
8/2/2012
Today’s report by the Generic Pharmaceutical Association (GPhA) documents one of the many benefits achieved by new medicines developed by biopharmaceutical research companies. Cost savings attributable to generic drugs represent one stage of the prescription drug lifecycle. Such savings are possible because innovator biopharmaceutical research companies – the most research-intensive sector in the U.S. economy – produce medical advances through pioneering scientific work and long-term, expensive investments. Over time, these innovative new medicines lead to generic copies that patients use at low cost for many years. Without the development of new medicines by innovator companies, there would be neither the new medicines essential to progress against diseases nor generic copies.
More
Patient Assistance Programs for HIV Get Boost from HHS Secretary Sebelius
7/23/2012
"We applaud the leadership of Secretary Sebelius in recognizing the importance of patient assistance programs for people with HIV who cannot afford their prescription medicines. PhRMA and its members will utilize the common online form for patients with HIV on its Partnership for Prescription Assistance (PPA) website which has been in existence since 2005. The common online form is another way to help accelerate access to available programs."
More
Joint Industry Statement: Internet Sales and Access to Safe Medicines
7/23/2012
More
Global pharmaceutical industry calls for broad-based cooperation to fight online sales of counterfeit medicines around the world
7/23/2012
More
Nearly 200 Medicines in Development for Mental Illnesses
7/11/2012
America’s biopharmaceutical research companies are developing 187 innovative medicines to help the nearly 60 million patients in the United States who are suffering from some form of mental illness. The medicines in development – all in either clinical trials or under review by the Food and Drug Administration – include 52 for depression, 37 for schizophrenia and 26 for anxiety disorders, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA).
More

Subscribe to our Email Updates